Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Lilly at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Lilly brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 1039. Lilly supports symposia on CLL and mantle cell lymphoma and hosts a theater session on pirtobrutinib. Its research covers the socioeconomic burden of CLL after the introduction of newer treatments.

OrganizationASH 2026 Attendance
Lilly
Indianapolis, IN
Large pharma
Global pharmaceutical company based in Indianapolis whose oncology portfolio includes the BTK inhibitor pirtobrutinib for CLL and mantle cell lymphoma.
Booth
Exhibiting at Booth 1039
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia
How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research.
Lymphoma
Symposium
Fri Dec 11
11:00am–2:00pm
CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies
Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments.
Symposium hosted by Decera Clinical Education
Lymphoma
Symposium
Fri Dec 11
11:00am–2:00pm
Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies
Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
7:00pm–10:00pm
Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL
Continuous kinase inhibitors versus fixed-duration Bcl-2 combinations for chronic lymphocytic leukemia, weighed against recent phase 3 trial results.
Lymphoma

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Lilly

Tell us what you sell and we’ll find the people at Lilly most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction